Tim Heise1, Jens Jordan2, Christoph Wanner3, Martina Heer4, Sreeraj Macha5, Michaela Mattheus6, Søren S Lund6, Hans J Woerle6, Uli C Broedl6. 1. Profil, Neuss, Germany. Electronic address: tim.heise@profil.com. 2. Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany. 3. Renal Division, University of Würzburg, Würzburg, Germany. 4. Profil, Neuss, Germany. 5. Merck & Co., Inc. Kenilworth, New Jersey, USA. 6. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Abstract
PURPOSE: The goal of this study was to investigate the pharmacodynamic effects of co-administration of empagliflozin, a sodium glucose cotransporter 2 inhibitor, with diuretic agents. METHODS: In a randomized, open-label cross-over study, 22 patients with type 2 diabetes mellitus received empagliflozin 25 mg for 5 days and either hydrochlorothiazide 25 mg for 4 days followed by hydrochlorothiazide 25 mg plus empagliflozin 25 mg for 5 days, or torasemide 5 mg for 4 days followed by torasemide 5 mg plus empagliflozin 25 mg for 5 days; 20 completed treatment. Food, fluid, and sodium intake were standardized for 3 days before and during treatment. FINDINGS: At baseline, the median age of the treated patients was 56 years (range, 40-65 years), body mass index was 26.8 kg/m2 (range, 20.1-34.4 kg/m2), fasting plasma glucose was 8.6 mmol/L (range, 6.0-12.9 mmol/L), and glycosylated hemoglobin level was 7.6% (range, 7%-10%). Empagliflozin significantly increased 24-hour urinary glucose excretion and reduced fasting serum glucose levels. These effects were maintained after co-administration with either diuretic. Urinary sodium excretion did not significantly change with empagliflozin or diuretic administration alone, but seemed to increase compared with either diuretic alone when empagliflozin was co-administered with either diuretic. Plasma renin and serum aldosterone levels were unaltered with empagliflozin or torasemide alone, but tended to increase with hydrochlorothiazide alone, and tended to increase when empagliflozin was co-administered with a diuretic compared with either diuretic alone. Urinary volume did not increase with empagliflozin or diuretics alone, but increased when empagliflozin was co-administered with either diuretic. IMPLICATIONS: Empagliflozin alone for 5 days increased urinary glucose excretion but did not seem to have a relevant impact on urine volume or electrolytes. When empagliflozin was co-administered with a diuretic agent, urinary glucose excretion remained increased, and the renin-angiotensin system was activated. Clinicaltrials.gov identifier: NCT01276288.
RCT Entities:
PURPOSE: The goal of this study was to investigate the pharmacodynamic effects of co-administration of empagliflozin, a sodium glucose cotransporter 2 inhibitor, with diuretic agents. METHODS: In a randomized, open-label cross-over study, 22 patients with type 2 diabetes mellitus received empagliflozin 25 mg for 5 days and either hydrochlorothiazide 25 mg for 4 days followed by hydrochlorothiazide 25 mg plus empagliflozin 25 mg for 5 days, or torasemide 5 mg for 4 days followed by torasemide 5 mg plus empagliflozin 25 mg for 5 days; 20 completed treatment. Food, fluid, and sodium intake were standardized for 3 days before and during treatment. FINDINGS: At baseline, the median age of the treated patients was 56 years (range, 40-65 years), body mass index was 26.8 kg/m2 (range, 20.1-34.4 kg/m2), fasting plasma glucose was 8.6 mmol/L (range, 6.0-12.9 mmol/L), and glycosylated hemoglobin level was 7.6% (range, 7%-10%). Empagliflozin significantly increased 24-hour urinary glucose excretion and reduced fasting serum glucose levels. These effects were maintained after co-administration with either diuretic. Urinary sodium excretion did not significantly change with empagliflozin or diuretic administration alone, but seemed to increase compared with either diuretic alone when empagliflozin was co-administered with either diuretic. Plasma renin and serum aldosterone levels were unaltered with empagliflozin or torasemide alone, but tended to increase with hydrochlorothiazide alone, and tended to increase when empagliflozin was co-administered with a diuretic compared with either diuretic alone. Urinary volume did not increase with empagliflozin or diuretics alone, but increased when empagliflozin was co-administered with either diuretic. IMPLICATIONS: Empagliflozin alone for 5 days increased urinary glucose excretion but did not seem to have a relevant impact on urine volume or electrolytes. When empagliflozin was co-administered with a diuretic agent, urinary glucose excretion remained increased, and the renin-angiotensin system was activated. Clinicaltrials.gov identifier: NCT01276288.
Authors: David León Jiménez; David Z I Cherney; Petter Bjornstad; Luis Castilla-Guerra; José Pablo Miramontes González Journal: Am J Physiol Renal Physiol Date: 2018-08-01
Authors: David Fitchett; Silvio E Inzucchi; Christopher P Cannon; Darren K McGuire; Benjamin M Scirica; Odd Erik Johansen; Steven Sambevski; Stefan Kaspers; Egon Pfarr; Jyothis T George; Bernard Zinman Journal: Circulation Date: 2019-03-12 Impact factor: 29.690
Authors: Anna Solini; Livia Giannini; Marta Seghieri; Edoardo Vitolo; Stefano Taddei; Lorenzo Ghiadoni; Rosa Maria Bruno Journal: Cardiovasc Diabetol Date: 2017-10-23 Impact factor: 9.951
Authors: Silvio E Inzucchi; Kamlesh Khunti; David H Fitchett; Christoph Wanner; Michaela Mattheus; Jyothis T George; Anne Pernille Ofstad; Bernard Zinman Journal: J Clin Endocrinol Metab Date: 2020-09-01 Impact factor: 5.958
Authors: Subodh Verma; C David Mazer; David Fitchett; Silvio E Inzucchi; Egon Pfarr; Jyothis T George; Bernard Zinman Journal: Diabetologia Date: 2018-05-19 Impact factor: 10.122